ROIV:NASDAQ
Roivant Sciences Ltd
$40.94
arrow_downward
-2.08%(-0.87) 1D
$40.72
arrow_downward
-0.54% (-0.22)bedtimeAfter hours
Closed: Sep 10, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$41.26
High
$41.40
Low
$40.22
Mkt. cap
29.57B
Avg. vol.
7.84M
Volume
0.00
52-wk high
$42.50
52-wk low
$13.81
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
Open
$41.26
High
$41.40
Low
$40.22
Mkt. cap
29.57B
Avg. vol.
7.84M
Volume
0.00
52-wk high
$42.50
52-wk low
$13.81
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
News stories
From web sources and news partners
Stock Titan
·
6 hours ago
Roivant Sciences (ROIV) director sells stock under preset plan
Seeking Alpha
·
8 hours ago
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD - Slideshow
Stocktwits
·
9 hours ago
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?
TradingView
·
16 hours ago
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd